Octapharma Group and Fresenius Kabi have signed a license, development and supply agreement regarding the use of latter’s HESylation Technology to develop a HESylated recombinant protein.
Under the agreement, Fresenius Kabi will license its proprietary HESylation Technology to Octapharma. This technology platform is based on hydroxyethyl starch (HES) which will be combined with a recombinant protein from Octapharma’s human cell-line platform. This combination is intended to generate a therapeutic protein with a superior product profile.
Reportedly, Fresenius Kabi will seek to adapt and optimise the protein modification by its HESylation Technology and will afterwards be responsible for providing the appropriate HES derivative to Octapharma.
As per the deal, Octapharma will oversee the further development and commercialisation. Fresenius Kabi will receive up-front and milestone payments, research funding and royalties on sales for licensing of the HESylation Technology.